Search Results - "Haynes, Andrew S"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia by Haynes, Andrew S, Maples, Holly, Parker, Sarah

    “…Abstract Vancomycin remains the standard of care for treating methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in pediatrics largely because no…”
    Get full text
    Journal Article
  2. 2

    Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections by Haynes, Andrew S, Wei, Zixuan, Anderson, Peter, Scheetz, Marc H, Parker, Sarah K, Fish, Douglas N

    Published in Antimicrobial agents and chemotherapy (02-05-2024)
    “…Cephalexin, a first-generation cephalosporin, is the first-line oral therapy for children with musculoskeletal infections due to methicillin-susceptible…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19 by DeVine, Mackenzie N., Maxwell, Sarah, Haynes, Andrew S., MacBrayne, Christine E., Boguniewicz, Juri

    Published in Journal of pediatric hematology/oncology (01-01-2022)
    “…Relapse of infection due to SARS-CoV-2 has been rarely described and there is little guidance regarding the management of such cases in immunocompromised…”
    Get full text
    Journal Article
  5. 5

    Cefadroxil Comparable to Cephalexin: Minimum Inhibitory Concentrations among Methicillin-Susceptible Staphylococcus aureus Isolates from Pediatric Musculoskeletal Infections by Haynes, Andrew S., Prinzi, Andrea, Silveira, Lori J., Parker, Sarah K., Lampe, Jed N., Kavanaugh, Jeffrey S., Horswill, Alexander R., Fish, Douglas

    Published in Microbiology spectrum (31-08-2022)
    “…Cephalexin and cefadroxil are oral first-generation cephalosporins used to treat methicillin-susceptible Staphylococcus aureus (MSSA) infections. Despite its…”
    Get full text
    Journal Article
  6. 6

    An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT by Haynes, Andrew S., Curtis, Donna J., Campbell, Kristen, Giller, Roger H., Quinones, Ralph R., Verneris, Michael R., Abzug, Mark J.

    Published in Transplantation and cellular therapy (01-04-2021)
    “…Following hematopoietic stem cell transplant (HSCT), patients are at increased risk of vaccine-preventable diseases (VPDs) and experience worse outcomes of…”
    Get full text
    Journal Article
  7. 7